Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida

Clinical-Stage Developer of Vaccines for Cancer & Metastatic Disease moves into closer proximity to collaborators at Mayo Clinic in Jacksonville JACKSONVILLE, Florida, November 5, 2015 /PRNewswire/ – TapImmune Inc., (TPIV) a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced…

TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015

JACKSONVILLE, Florida, October 7, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the Aegis Capital Corp. 2015 Growth Conference, at the Encore Wynn Hotel in…

TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization JACKSONVILLE, Florida, September 15, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II…

TapImmune Announces Finalization of License Agreement With Mayo Clinic To Commercialize a Folate Receptor Alpha Vaccine for Multiple Cancer Indications

Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials SEATTLE, July 27, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, is pleased to announce that the Company has exercised its option agreement with Mayo Clinic. TapImmune has signed a…

TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation

SEATTLE, June 2, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, and its institutional investors have reached an agreement whereby the institutional investors will have the option to exercise their short term warrants to provide the Company up to $4.93M in near term funding, pending closing conditions and an effective S-1…

TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

SEATTLE, March 19, 2015 – TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company’s Board of Directors. David brings 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical and healthcare products. He has a successful track record of building, developing, operating and…

TapImmune Appoints John Bonfiglio as Strategic Advisor

Accomplished Biotech CEO to provide Capital Market, Financing and Drug Development Expertise SEATTLE, Feb. 25, 2015 – TapImmune Inc. (TPIV) has pleasure in announcing the appointment of John Bonfiglio, Ph.D., MBA as a Strategic Advisor. John is a highly successful Biotech CEO with broad experience in corporate strategy and financing, market interactions and business development.…